March & April 2025 Psychedelic Patent Update: Lykos’ Patent Woes Continue; Filings Provide First Look at Seaport’s 2-Bromo-LSD Program; Delix’s Ergoline Analogues; CaaMTech’s Spinout

Written by Psychedelic Alpha’s Noah Smith with support from Editor-at-Large and patent attorney Graham Pechenik of Calyx Law.

The Psychedelic Patent Update provides headline figures and data regarding published psychedelic patent applications and grants, as well as a brief summary of a select handful of patent-related actions.

General Overview

We added 31 PCTs and 45 U.S. patent applications focused on psychedelics to our tracker in the months of March and April 2025. New entries came from the likes of Seaport Therapeutics, Gilgamesh Pharmaceuticals, Lykos Therapeutics, Terran Biosciences, Delix Therapeutics, and more.

Using our interface, you can explore applications that were not only published or granted in these months, but also those that were allowed, abandoned, rejected, or even instances where applicants filed responses to final and non-final rejections from Examiners.

Log-in to your Pα+ account, or join today, to explore the data and continue reading.